- Home
- TNGX vs NMM Comparison
TNGX vs NMM Comparison
Compare TNGX & NMM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TNGX | NMM |
|---|---|---|
| Founded | 2014 | 2007 |
| Country | United States | Greece |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Marine Transportation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.7B |
| IPO Year | N/A | 2007 |
Fundamental Metrics
Financial Performance| Metric | TNGX | NMM |
|---|---|---|
| Price | $12.51 | $60.22 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $13.00 | N/A |
| AVG Volume (30 Days) | ★ 3.1M | 108.4K |
| Earning Date | 02-26-2026 | 02-10-2026 |
| Dividend Yield | N/A | ★ 0.34% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 8.91 |
| Revenue | $66,501,000.00 | ★ $1,311,114,000.00 |
| Revenue This Year | $52.80 | N/A |
| Revenue Next Year | N/A | $15.74 |
| P/E Ratio | ★ N/A | $6.61 |
| Revenue Growth | ★ 53.29 | N/A |
| 52 Week Low | $1.03 | $28.37 |
| 52 Week High | $13.46 | $61.82 |
Technical Indicators
Market Signals| Indicator | TNGX | NMM |
|---|---|---|
| Relative Strength Index (RSI) | 62.52 | 61.10 |
| Support Level | $11.69 | $58.80 |
| Resistance Level | $12.96 | $61.82 |
| Average True Range (ATR) | 0.78 | 1.35 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 81.65 | 57.81 |
Price Performance
Historical ComparisonAbout TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About NMM Navios Maritime Partners LP
Navios Maritime Partners LP is a seaborne shipping company. It owns and operates dry cargo and container vessels with the primary long-term and staggered expiration charters. The firm's fleet consists of Ultra- Handymax, Panamax, Capsize, and Container vessels and categorized in Drybulk and Container vessels. It earns revenue through the chartering of vessels and voyage contracts. Geographically, it generates majority revenue from Asia.